The Prange Group and its affiliate Adragos Pharma, a European CDMO, has completed the acquisition transaction of Fresenius Kabi production site in Halden, Norway - a leading sterile pharmaceutical manufacturing unit.
This strategic move opens the door to considerable new opportunities for growth. It marks a major milestone for both the Prange Group and Adragos Pharma on the road to expanding their global presence and adding significant capacity for sterile liquid manufacturing.
The Halden site, situated at a strategic crossroads in Norway, is one of the largest and most advanced sterile production facilities in Northern Europe.
Its capabilities include the production of sterile liquids, IV bags, blow-fill-seal technology for ampoules and vials, but also compounding activities for the local market.
The site was not only a cornerstone of Fresenius Kabi’s manufacturing capabilities in the Nordics, but has already catered to other large pharma customers as a contract manufacturer supplying over 70 countries worldwide.
The Prange Group is a leading German family business with a long track record of successfully investing in and growing pharmaceutical companies and CDMOs.
It has invested in Adragos Pharma from its inception and remains a cornerstone shareholder, reflecting its long term commitment to the sector.
Otto Prange, Chairman and Owner of the Prange group added: “We appreciate Fresenius Kabi for trusting in our Group as being the right partner for building the future of the Halden site. Together with the experienced Halden team, we will introduce new customers who can rely as well as Fresenius and the other big pharma customers on our full commitment for reliable, global supply”.
